RemedyMD in research deal with ALS Association
Tuesday 15th April 2008

RemedyMD, a leading provider of clinical and translational research solutions, has announced an agreement with The ALS Association's research department, which will implement its Investigate research software suite in three phases across TREAT ALS, its translational research portfolio.

The ALS Association is the only not-for-profit voluntary health organisation dedicated solely to the fight against amyotrophic lateral sclerosis, more commonly known as motor neurone disease or Lou Gehrig's Disease.

Investigate's web-based technology enables full grant management and researcher collaboration, as well as the aggregation, mining and cross-referencing of data. The goal is to increase commercialisation opportunities and translate research results more rapidly into effective treatments.

"Using RemedyMD's technology we will integrate ALS research knowledge, greatly enhancing our ability to design, lead, manage and communicate about research initiatives to researchers and the broader clinical, patient and donor community," said Lucie Bruijn, PhD, Science Director and Vice President for The ALS Association.

"Forward thinking, adaptable and cost-efficient technology investments are a critical strategic tool for disease focused organisations such as The ALS Association, enabling them to leverage vast knowledge bases to be more effective at directing research and other core activities. The vision is to converge clinical/patient, research, legislative and donor/investor data onto a unified system to make clinical research more effective, more quickly."

Michael Malone, President and COO of RemedyMD, said: "We look forward to a very productive relationship with The ALS Association. Investigate will play a pivotal role in their mission to move more discoveries from bench to bedside."

http://www.hospitaliteurope.com/defa...ticle.id=10099